Balyasny Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,026
| Closed | -$1.2M | – | 2846 |
|
|
2025
Q4 | $1.2M | Sell |
3,026
-7,234
| -71% | -$3.2M | ﹤0.01% | 2103 |
|
|
2025
Q3 | $4.68M | Sell |
10,260
-105,015
| -91% | -$42.8M | 0.01% | 1394 |
|
|
2025
Q2 | $37.6M | Buy |
115,275
+102,159
| +779% | +$28.3M | 0.06% | 431 |
|
|
2025
Q1 | $3.54M | Buy |
+13,116
| New | +$3.37M | 0.01% | 1418 |
|
|
2024
Q4 | – | Sell |
-33,405
| Closed | -$8.79M | – | 2690 |
|
|
2024
Q3 | $9.19M | Buy |
+33,405
| New | +$8.7M | 0.02% | 998 |
|
|
2024
Q2 | – | Sell |
-287,627
| Closed | -$43M | – | 2528 |
|
|
2024
Q1 | $43M | Buy |
+287,627
| New | +$48M | 0.08% | 351 |
|
|
2023
Q2 | – | Sell |
-251,798
| Closed | -$50.4M | – | 2238 |
|
|
2023
Q1 | $50.4M | Buy |
251,798
+251,279
| +48,416% | +$52.8M | 0.13% | 213 |
|
|
2022
Q4 | $123K | Sell |
519
-47,259
| -99% | -$10.1M | ﹤0.01% | 2219 |
|
|
2022
Q3 | $9.56M | Sell |
47,778
-15,732
| -25% | -$3M | 0.03% | 707 |
|
|
2022
Q2 | $9.26M | Buy |
+63,510
| New | +$9.01M | 0.03% | 683 |
|
|
2022
Q1 | – | Sell |
-81,241
| Closed | -$12.4M | – | 2441 |
|
|
2021
Q4 | $13.8M | Buy |
81,241
+41,097
| +102% | +$7.64M | 0.05% | 541 |
|
|
2021
Q3 | $7.58M | Buy |
40,144
+16,652
| +71% | +$3.12M | 0.03% | 679 |
|
|
2021
Q2 | $3.98M | Sell |
23,492
-99,707
| -81% | -$14.6M | 0.02% | 785 |
|
|
2021
Q1 | $17.4M | Buy |
123,199
+118,699
| +2,638% | +$17.9M | 0.09% | 313 |
|
|
2020
Q4 | $585K | Sell |
4,500
-53,774
| -92% | -$7.18M | ﹤0.01% | 1103 |
|
|
2020
Q3 | $8.48M | Buy |
+58,274
| New | +$8.28M | 0.06% | 442 |
|
|
2018
Q4 | – | Sell |
-10,046
| Closed | -$879K | – | 1361 |
|
|
2018
Q3 | $879K | Sell |
10,046
-235,670
| -96% | -$23.7M | ﹤0.01% | 1217 |
|
|
2018
Q2 | $24.2M | Buy |
+245,716
| New | +$24.4M | 0.11% | 265 |
|
|
2018
Q1 | – | Sell |
-7,676
| Closed | -$990K | – | 1902 |
|
|
2017
Q4 | $975K | Buy |
+7,676
| New | +$965K | ﹤0.01% | 1340 |
|
|
2017
Q3 | – | Sell |
-8,861
| Closed | -$707K | – | 1850 |
|
|
2017
Q2 | $707K | Sell |
8,861
-194,606
| -96% | -$12.4M | ﹤0.01% | 1178 |
|
|
2017
Q1 | $10.4M | Sell |
203,467
-139,355
| -41% | -$6.44M | 0.05% | 479 |
|
|
2016
Q4 | $12.8M | Buy |
+342,822
| New | +$14.4M | 0.07% | 408 |
|
|
2016
Q2 | – | Sell |
-55,671
| Closed | -$3.49M | – | 1138 |
|
|
2016
Q1 | $3.49M | Buy |
+55,671
| New | +$3.7M | 0.02% | 612 |
|
|
2015
Q3 | – | Sell |
-2,325
| Closed | -$279K | – | 1130 |
|
|
2015
Q2 | $279K | Buy |
+2,325
| New | +$278K | ﹤0.01% | 965 |
|
Other funds holding ALNY
VPM
VCM
Balyasny Asset Management's ALNY Position: Q1 2026 in Review
Balyasny Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 3,026 shares — an estimated $1.2M sold.
Balyasny Asset Management first reported a position in ALNY in Q2 2015 and held it in 24 quarters. The position peaked at $50.4M in Q1 2023. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Balyasny Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Balyasny Asset Management sold 3,026 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.2M.
- Balyasny Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2015 and held it in 24 quarters.
- Balyasny Asset Management's Alnylam Pharmaceuticals position peaked at $50.4M in Q1 2023.
- 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.